Organisation paid for research Program year 2025 Source: CMS Open Payments

K2 Medical Research

Neither a doctor nor a teaching hospital

Research payments

$6,332,669

310 payments

Through program year 2025, K2 Medical Research is reported as receiving $6,332,669 in research payments, across 310 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $1,537,486 128
2024 Research $1,714,471 61
2023 Research $2,874,761 114
2022 Research $205,950 7

Breakdown

Who paid Research payments · program years 2022–2025
  1. Biogen, Inc. $2,961,003 7 payments
  2. Eisai Inc. $1,817,860 54 payments
  3. E.R. Squibb & Sons, L.L.C. $918,811 12 payments
  4. Novo Nordisk AS $238,343 65 payments
  5. Alnylam Pharmaceuticals Inc. $168,665 46 payments
  6. AbbVie, Inc. $146,054 42 payments
  7. Novartis Pharmaceuticals Corporation $55,813 4 payments
  8. Celgene Corporation $19,000 1 payment
  9. Sumitomo Pharma America, Inc. $4,680 77 payments
  10. Boehringer Ingelheim International GmbH $2,440 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $2,961,003 7 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $941,305 42 payments
  3. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $876,555 12 payments
  4. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $461,911 4 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease $303,284 3 payments
  6. Nn6535-4725 $238,343 65 payments
  7. A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) $168,665 46 payments
  8. Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD $84,981 20 payments
  9. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $81,681 1 payment
  10. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $67,438 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record